All In Biotech

Free tool

FAERS Monitor: Xopenex Hfa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021730 or its brand name (Xopenex Hfa, Levalbuterol Tartrate). Reports on generic versions are filed under their own applications.

Reports

3,733

Serious

1,628

44% of reports

Hospitalization

783

Death reported

129

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device delivery system issue642
  • drug dose omission by device556
  • no adverse event510
  • dyspnoea440
  • headache244
  • nausea229
  • fatigue225
  • cough213
  • asthma210
  • off label use197
  • dizziness174
  • pneumonia172
  • drug ineffective166
  • diarrhoea153
  • sinusitis152

Reports by year received

View as table
YearReports
20067
200724
200845
200933
201028
201142
201278
201378
201492
2015141
2016294
2017190
2018167
2019190
2020210
2021145
2022178
2023358
2024471
2025545
2026417

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device delivery system issueSignal642135.3125.983,534
drug dose omission by deviceSignal55640.337.321,189
no adverse eventSignal51015.914.77,148
asthmaSignal21010.59.21,799
sinusitisSignal1528.47.2982
dyspnoeaSignal4404.44.01,176
coughSignal2134.33.8539
pneumoniaSignal1723.02.6230
headacheSignal2442.21.9162
dizziness1742.01.784
nausea2291.61.457
fatigue2251.61.456
diarrhoea1531.31.113
off label use1971.31.111
drug ineffective1660.70.621

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.